nach oben

Erschienen in:

25.06.2020 | Lipidstoffwechselstörungen | FORTBILDUNG

HIV-Infektion und Lipidentgleisung — Gründe und Gegenmaßnahmen

Kardiovaskuläre Erkrankungen

verfasst von: Dr. med. Tim Hollstein, Friederike Schumann, Dr. med. Ursula Kassner

Erschienen in: MMW - Fortschritte der Medizin | Sonderheft 2/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Infektion mit dem Humanen Immundefizienz-Virus (HIV) führt zu einer bedeutenden Erhöhung des kardiovaskulären Risikos. Im folgenden CME-Kurs erfahren Sie, warum das so ist, und welche therapeutischen Maßnahmen erforderlich sind, um HIV-Patienten möglichst optimal vor kardiovaskulären Ereignissen zu schützen.

Palella FJ, Delaney KM, Moorman AC et al. Declining Morbidity and Mortality among Patients with Advanced Human Immunodefciency Virus Infection. New England Journal of Medicine. 1998;338:853–60.PubMed

Collaboration TATAC. HIV treatment response and prognosis in Europe and North America in the frst decade of highly active antiretroviral therapy: a collaborative analysis. The Lancet. 2006;368(9534):451–8.

Samji H, Cescon A, Hogg RS et al. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLoS ONE. 2013;8(12):e81355.PubMedPubMedCentral

Shah ASV, Stelzle D, Lee KK et al. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV. Circulation. 2018;138:1100–12.PubMedPubMedCentral

Alonso A, Barnes AE, Guest JL, Shah A, Shao IY, Marconi V. HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a Large Healthcare Database. Journal of the American Heart Association. 2019;8(14):e012241.PubMedPubMedCentral

Feinstein MJ, Bahiru E, Achenbach C et al. Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013. The American Journal of Cardiology. 2016;117:214–20.PubMed

Marincowitz C, Genis A, Goswami N, De Boever P, Nawrot TS, Strijdom H. Vascular endothelial dysfunction in the wake of HIV and ART. The FEBS J. 2019;286:1256–70.PubMed

Calmy A, Gayet-Ageron A, Montecucco F et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009;23:929–39.PubMed

Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodefciency virus infection and the acquired immunodefciency syndrome. 1992;74:1045–52.

10.

Mujawar Z, Rose H, Morrow MP et al. Human Immunodefciency Virus Impairs Reverse Cholesterol Transport from Macrophages. PLoS Biology. 2006;4:e365.PubMedPubMedCentral

11.

Brath H, Grabovac I, Schalk H, Degen O, Dorner TE. Prevalence and Correlates of Smoking and Readiness to Quit Smoking in People Living with HIV in Austria and Germany. 2016;11:e0150553.

12.

Rasmussen LD, Helleberg M, May MT et al. Myocardial Infarction Among Danish HIV-Infected Individuals: Population-Attributable Fractions Associated With Smoking. Clin Infect Dis. 2015;60:1415–23.PubMed

13.

Helleberg M, Afzal S, Kronborg G et al. Mortality Attributable to Smoking Among HIV-1—Infected Individuals: A Nationwide, Population-Based Cohort Study. Clin Infect Dis. 2013;56:727–34.PubMed

14.

Joy T, Keogh HM, Hadigan C et al. Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. 2007;21(12):1591–1600.

15.

Lai S, Fishman EK, Lai H et al. Long-Term Cocaine Use and Antiretroviral Therapy Are Associated with Silent Coronary Artery Disease in African Americans with HIV Infection Who Have No Cardiovascular Symptoms. Clin Infect Dis. 2008;46:600–10.PubMedPubMedCentral

16.

Lorenz DR, Dutta A, Mukerji SS, Holman A, Uno H, Gabuzda D. Marijuana Use Impacts Midlife Cardiovascular Events in HIV-Infected Men. Clin Infect Dis. 2017;65:626–35.PubMedPubMedCentral

17.

Group TDCoAEoA-HDDS. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. N Engl J Med. 2003;349:1993–2003.

18.

Group TDS. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. N Engl J Med. 2007;356:1723–35.

19.

Kaplan RC, Kingsley LA, Sharrett AR et al. Ten-Year Predicted Coronary Heart Disease Risk in HIV-Infected Men and Women. Clin Infect Dis. 2007;45:1074–81.PubMed

20.

Stein JH, Hsue PY. Infammation, Immune Activation, and CVD Risk in Individuals With HIV Infection. JAMA. 2012;308:405.PubMed

21.

Hadigan C, Meigs JB, Wilson PWF et al. Prediction of Coronary Heart Disease Risk in HIV-Infected Patients with Fat Redistribution. Clin Infect Dis. 2003;36:909–16.PubMed

22.

Worm SW, Friis-Møller N, Bruyand M et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different defnitions of the metabolic syndrome. AIDS. 2010;24:427–35.PubMed

23.

Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodefciency Virus Disease. Clin Endocrinol Metab. 2007;92:2506–12.

24.

Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58.PubMed

25.

Group TSfMoATSS. CD4+ Count—Guided Interruption of Antiretroviral Treatment. N Engl J of Med. 2006;355:2283–96.

26.

Marcus JL, Neugebauer RS, Leyden WA et al. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. J Acquir Immune Defc Syndr. 2016;71:413–9.

27.

Strategies for Management of Anti-Retroviral Therapy I, Groups DADS. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17–F24.

28.

Panel EM. EACS Guidelines Version 10.0. Practice Guideline. 2019.

29.

Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L et al. Treatment with tenofovir alafenamide fumarate worsens the lipid profle of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Basic Clin Pharmacol Toxicol. 2019;124:479–90.PubMed

30.

Gallant JE, Daar ES, Raf F et al. Efcacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fxed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ. The Lancet HIV. 2016;3:e158–e165.PubMed

31.

Wohl D, Oka S, Clumeck N et al. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defc Syndr. 2016;72:58–64.

32.

Gebhardt A, Fichtenbaum CJ. Current pharmacotherapy for the treatment of dyslipidemia associated with HIV infection. Expert Opin Pharmacother. 2019;20:1719–29.PubMed

33.

Ryom L, Lundgren JD, El-Sadr W et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. The Lancet HIV. 2018;5:e291–e300.PubMed

34.

Stein JH, Ribaudo HJ, Hodis HN et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS. 2015;29:1775–83.PubMedPubMedCentral

35.

Lafeur J, Bress AP, Rosenblatt L et al. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS. 2017;31:2095–106.

36.

Tebas P, Sension M, Arribas J et al. Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1—Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials. Clin Infect Dis. 2014;59:425–34.PubMed

37.

Molina J-M, Squires K, Sax PE et al. Doravirine versus ritonavirboosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, doubleblind, phase 3, non-inferiority trial. The Lancet HIV. 2018;5:e211–e220.PubMed

38.

Ciaf L, Cavassini M, Genne D et al. Switch to etravirine for HIVpositive patients receiving statin treatment: a prospective study. Eur J Clin Invest. 2015;45:720–30.

39.

Ofotokun I, Na LH, Landovitz RJ et al. Comparison of the Metabolic Efects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257. Clin Infect Dis. 2015;60:1842–51.PubMedPubMedCentral

40.

Fung HB, Guo Y. Enfuvirtide: A fusion inhibitor for the treatment of HIV infection. Clin Ther. 2004;26:352–78.PubMed

41.

Daar ES, Dejesus E, Ruane P et al. Efcacy and safety of switching to fxed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph. The Lancet HIV. 2018;5:e347–e356.PubMed

42.

Martínez E, Larrousse M, Llibre JM et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24:1697–1707.PubMed

43.

Gatell JM, Assoumou L, Moyle G et al. Immediate Versus Deferred Switching From a Boosted Protease Inhibitor—based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study. Clin Infect Dis. 2019;68:597–606.PubMed

44.

Bourgi K, Rebeiro PF, Turner M et al. Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy. Clin Infect Dis. 2020;70:1267–74.PubMed

45.

Grunfeld C. Dyslipidemia and its Treatment in HIV Infection. Top HIV Med. 2010;18:112–8.PubMedPubMedCentral

46.

Macinnes A, Lazzarin A, Di Perri G et al. Maraviroc Can Improve Lipid Profles in Dyslipidemic Patients with HIV: Results from the MERIT Trial. HIV Clin Trials. 2011;12:24–36.PubMed

47.

Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modifcation to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.PubMed

48.

Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:1–10.

49.

Zanetti HR, Gonçalves A, Teixeira Paranhos Lopes L et al. Efects of Exercise Training and Statin Use in People Living with Human Immunodefciency Virus with Dyslipidemia. Medicine and science in sports and exercise. Med Sci Sports Exerc. 2020;52:16–24.PubMed

50.

Lazzaretti RK, Kuhmmer R, Sprinz E, Polanczyk CA, Ribeiro JP. Dietary Intervention Prevents Dyslipidemia Associated With Highly Active Antiretroviral Therapy in Human Immunodefciency Virus Type 1—Infected Individuals. J Am Coll Cardiol. 2012;59:979–88.PubMed

51.

Gutierrez MDM, Mateo MG, Corbacho N, Vidal F, Domingo P. Drug-drug interactions when treating HIV-related metabolic disorders. Expert Opinion on Drug Metabolism & Toxicology. 2019:1–16.

52.

Gerber JG, Rosenkranz SL, Fichtenbaum CJ et al. Efect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defc Syndr. 2005;39:307–12.

53.

Kakuda TN, Schöller-Gyüre M, Hoetelmans RMW. Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs. Clin Pharmacokinet. 2011 Jan;50:25–39.PubMed

54.

Erlandson KM, Jiang Y, Debanne SM, McComsey GA. Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy. Clin Infect Dis. 2015; 61: 1566–72.PubMedPubMedCentral

55.

Khalilieh S, Yee KL, Sanchez RI et al. Results of a doravirineatorvastatin drug-drug interaction study. 2016:AAC.01364–01316.

56.

van Luin M, Colbers A, van Ewijk-Beneken Kolmer EWJ et al. Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. J Acquir Immune Defc Syndr. 2010;55:82–6.

57.

Negredo E, Moltó J, Puig J et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS. 2006;20(17):2159–64.PubMed

58.

Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020;41:99–109c.PubMed

59.

Feinstein MJ, Hsue PY, Benjamin LA et al. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientifc Statement From the American Heart Association. Circulation. 2019;140(2):e98–e124.PubMed

60.

Amend KL, Landon J, Thyagarajan V, Niemcryk S, McAfee A. Incidence of Hospitalized Rhabdomyolysis with Statin and Fibrate Use in an Insured US Population. Ann Pharmacother. 2011;45:1230–9.PubMed

61.

Longenecker CT et al. Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis. 2016;29:1–9PubMedPubMedCentral

Titel: HIV-Infektion und Lipidentgleisung — Gründe und Gegenmaßnahmen
Kardiovaskuläre Erkrankungen
verfasst von: Dr. med. Tim Hollstein
Friederike Schumann
Dr. med. Ursula Kassner
Publikationsdatum: 25.06.2020
Verlag: Springer Medizin
Schlagwörter: Lipidstoffwechselstörungen
HIV
Statine
Pravastatin
Fibrate
Erschienen in: MMW - Fortschritte der Medizin / Ausgabe Sonderheft 2/2020
Print ISSN: 1438-3276
Elektronische ISSN: 1613-3560
DOI: https://doi.org/10.1007/s15006-020-0015-9

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

25.04.2024 | Hypotonie | Nachrichten

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

HIV-Infektion und Lipidentgleisung — Gründe und Gegenmaßnahmen

Kardiovaskuläre Erkrankungen

Zusammenfassung

Leitlinien kompakt für die Allgemeinmedizin

Facharzt-Training Allgemeinmedizin

Neu im Fachgebiet Allgemeinmedizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – Richtig schwierig wird es bei Profisportlern

Update Allgemeinmedizin

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2020

Denken Sie bei HIV-Infizierten auch ans Herz!

NNRTI schafft es in die deutsch-österreichischen Leitlinien

Nierenerkrankungen bei HIV-Patienten: Genügen Kreatininwert und Urinstix?

Dieser Nagel verrät die HIV-Medikation

PrEP bei akuter HIV-Infektion

Leben mit der HIV-Infektion

Leitlinien kompakt für die Allgemeinmedizin

Facharzt-Training Allgemeinmedizin

Neu im Fachgebiet Allgemeinmedizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – Richtig schwierig wird es bei Profisportlern

Update Allgemeinmedizin